These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15179440)

  • 41. Evaluation and management of heterotopic ossification in patients with spinal cord injury.
    Banovac K; Gonzalez F
    Spinal Cord; 1997 Mar; 35(3):158-62. PubMed ID: 9076866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preemptive rofecoxib and dexamethasone for prevention of pain and trismus following third molar surgery *.
    Moore PA; Brar P; Smiga ER; Costello BJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Feb; 99(2):E1-7. PubMed ID: 15660075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic prophylaxis for heterotopic ossification following spinal cord injury: A systematic review and meta-analysi.
    Yolcu YU; Wahood W; Goyal A; Alvi MA; Reeves RK; Qu W; Gerberi DJ; Bydon M
    Clin Neurol Neurosurg; 2020 Jun; 193():105737. PubMed ID: 32169744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
    Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
    Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease.
    Title LM; Giddens K; McInerney MM; McQueen MJ; Nassar BA
    J Am Coll Cardiol; 2003 Nov; 42(10):1747-53. PubMed ID: 14642682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
    N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery].
    Liu W; Loo CC; Tan HM; Ye TH; Ren HZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):666-70. PubMed ID: 15663229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. C-reactive protein and erythrocyte sedimentation rate in patients with heterotopic ossification after spinal cord injury.
    Estrores IM; Harrington A; Banovac K
    J Spinal Cord Med; 2004; 27(5):434-7. PubMed ID: 15648796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ankylosing spondylitis does not increase the risk of neurogenic heterotopic ossification in patients with a spinal cord injury: a retrospective cohort study.
    Ohlmeier M; Karras P; Suero EM; Grasmücke D; Aach M; Meindl R; Schildhauer TA; Citak M
    Spinal Cord; 2017 Feb; 55(2):213-215. PubMed ID: 27752058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-hospital outcomes following single-dose radiation therapy in the treatment of heterotopic ossification of the hip following spinal cord injury-an analysis of 444 cases.
    Müseler AC; Grasmücke D; Jansen O; Aach M; Meindl R; Schildhauer TA; Citak M
    Spinal Cord; 2017 Mar; 55(3):244-246. PubMed ID: 27431658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report).
    Stover SL; Hahn HR; Miller JM
    Paraplegia; 1976 Aug; 14(2):146-56. PubMed ID: 823516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP.
    Finerman GA; Stover SL
    Metab Bone Dis Relat Res; 1981; 3(4-5):337-42. PubMed ID: 6820114
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury.
    Singh RS; Craig MC; Katholi CR; Jackson AB; Mountz JM
    Arch Phys Med Rehabil; 2003 Nov; 84(11):1584-8. PubMed ID: 14639555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence of heterotopic ossification after hip arthroplasty: six-month follow-up.
    Buvanendran A; Kroin JS; Berger RA
    Anesthesiology; 2007 Aug; 107(2):358-9. PubMed ID: 17667588
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical Prediction Rule for Heterotopic Ossification of the Hip in Patients with Spinal Cord Injury.
    Suero EM; Meindl R; Schildhauer TA; Citak M
    Spine (Phila Pa 1976); 2018 Nov; 43(22):1572-1578. PubMed ID: 29652785
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial.
    Hefler LA; Grimm C; Speiser P; Sliutz G; Reinthaller A
    Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):251-4. PubMed ID: 16188370
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The sensitivity of ultrasound screening examination in detecting heterotopic ossification following spinal cord injury.
    Rosteius T; Suero EM; Grasmücke D; Aach M; Gisevius A; Ohlmeier M; Meindl R; Schildhauer TA; Citak M
    Spinal Cord; 2017 Jan; 55(1):71-73. PubMed ID: 27349610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulse low-intensity electromagnetic field as prophylaxis of heterotopic ossification in patients with traumatic spinal cord injury.
    Durović A; Miljković D; Brdareski Z; Plavsić A; Jevtić M
    Vojnosanit Pregl; 2009 Jan; 66(1):22-8. PubMed ID: 19195259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.